




Top Medical Tech (Europe) Co., Ltd

Personalized Liquid Biopsy



About Us

Top Medical Tech is a pioneer in non-invasive cancer diagnostics. We offer a new and efficient way to fight against cancer through personalized diagnostics

We provide a new and better approach to health care based on each patient's unique genetic makeup to overcome the limitations of traditional medicine. This is based on a deep understanding of the mechanism of mutations and monitoring the individual genomic alterations that cause tumors to grow, change, and respond to treatment.


We have combined scientific research, and our breakthrough innovation in liquid biopsy to that allows the development of tests that have already handled thousands of samples in 2015. Our genomic tests not only provide a more effective and patient-friendly method of detection and monitoring cancer, but also help match patients to approved targeted therapies as well as drugs in clinical trials all based on a simple blood test.



Statistics of Samples Tested


✧ Samples received: 3584

- Tissue: 496; Plasma: 1677
- For research: 3110; for clinical applications: 474




✧ Total Clinical Samples Summary (Date to 16th, March, 2016), Total Samples: 558



Sample Types Distribution



✧ Actionable Mutations Detection Ratio



Our Liquid Biopsy Procedure:



The Challenges in ctDNA analysis are: sensitivity, accuracy and multiplexing. Based on our unique technology ER-seq (Enrich Rare Mutations Sequencing) we could overcome limitations, and achieve the following:


Detectable Mutation Type	SNV, Indel, CNV, SV
Sensitivity	~99%(SNV), ~98%(Indel), 100%(CNV), 100%(SV)
Specificity	~99.5%(SNV), ~95.5%(Indel), 95%(CNV), 100%(SV)
Technical Detection Limit	0.1%
Consistency Between Tissue & Plasma	82.7% (120 paired samples)

The technical parameters derived from: simulative samples, international standards. Assessment of standards including: SNV (75), Indel(46), CNV(8) and SV(14) locus.



We provide:


OncoDrug - Lung Cancer



Targeted Drugs for Lung Cancer (54) and Tested Genes (190)

FDA-approved for lung cancer treatment	Gefitinib, Erlotinib, Afatinib, Crizotinib, Ceritinib, AZD9291, Alectinib
FDA-approved for other cancers treatment, recommended by NCCN	Cabozantinib, Dabrafenib, Trastuzumab, Vemurafenib
FDA-approved for other cancers treatment, currently under clinical trials for lung cancer	Axitinib, Olaparib, Dasatinib, Vandetanib, Vorinostat, Lapatinib, Ruxolitinib, Istodax, Nintedanib, Ponatinib, Pertuzumab, Pazopanib, Trametinib, Sunitinib, Sorafenib, Temsirolimus, Vismodegib, Sirolimus, Imatinib, Everolimus
Currently under clinical trials in lung cancer	LOXO -101, Abemaciclib, Alpelisib(BYL719), AZD4547, AZD5363, BGJ398, Binimetinib, Buparlisib, CO-1686, Dacomitinib, EGF816, Entrectinib, GDC-0032, INC280, MK-2206, Ribociclib, Icotinib, Antroquinonol, Dovitinib, Neratinib


OncoDrug - Breast Cancer




Targeted Therapy Drugs for Breast Cancer (41) and Tested Genes (825)	
FDA-approved for breast cancer treatment	Trastuzumab, Pertuzumab, Lapatinib, T-DM1, Palbociclib, Everolimus, Hormones
FDA-approved for other cancers treatment; currently under clinical trials for breast cancer	Cetuximab, Panitumumab, Dabrafenib, Trametinib, Vemurafenib, Afatinib, Olaparib, Gefitinib, Erlotinib, Sirolimus, Temsirolimus
Currently under clinical trials in breast cancer	Veliparib, Rucaparib, Niraparib, Dovitinib, AZD4547, Neratinib\NVP-BE Z235, Buparlisib, Alpelisib, LY2835219, LEE011, Nintedanib, AZD8186, MK-2206, Lpatasertib, AZD5363, Dinaciclib, Gamma-secretase inhibitor, R1507, GDC-0032, Selumetinib, LY2157299, Icotinib

OncoDrug Testing: Increase the possibility of finding the right targeted therapy drugs

OncoDrug - Lung Cancer




OncoDrug - Breast Cancer



93 Targeted Therapy Drugs

(46 approved by FDA, 47 under clinical trials)



OncoDrug - Different Cancer Types, One Solution

Only one sample blood test will do 1041 genes, covered 99% solid tumours




Clinical Application:


Our testing could be applied to every stage of cancer patient care. It can detect most types of solid tumor at both early and advanced stages, suggesting that it could be used as an effective screening method for most patients. A measurement of the levels of ctDNA in blood can also be used to quickly estimate a patient's stage of cancer and survival chances.

We would propose the following which could involve ctDNA test to monitor the whole progress of cancer treatment:

🌀 Clinical Application — Medicine Treatment Patients




🌀 Clinical Application — Surgical Patients




Onco Monitoring & Drug - OncoMD
Onco Early Testing - OncoET
Onco Minimal Residual Disease - OncoMRD

🌀 Clinical Application Case

Molecular Tumour Burden and CT



Changes of Subcloning in Tumour



Turnaround Time:

10 working days (after sample verification)

Sample Requirement

Plasma + Blood Cell

Tissues: Surgery Tissues, Biopsy, FFPE



Contact:
service@topgene.co.uk

Website:
www.topgene.co.uk